# India Dry Age Related Macular Degeneration (AMD) Market > India Dry Age-Related Macular Degeneration (AMD) Market Research Report By Stage (early age-related macular degeneration, intermediate age-related macular degeneration, late age-related macular degeneration), By Age Group (above 75 years, above 60 years, above 40 years), By Diagnosis and Treatment (treatment, diagnosis), By Route of Administration (oral, injectables) and By End Users (hospitals & clinics, diagnostic centers, academic & research institutes) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 8.3% - **2024:** $ 238 Million - **2025:** $ 257.75 Million - **2035:** $ 572.12 Million - **Key Players:** Regeneron Pharmaceuticals (US), Novartis (CH), Roche (CH), Bayer (DE), Pfizer (US), Alcon (CH), Horizon Therapeutics (IE), Apellis Pharmaceuticals (US), Santen Pharmaceutical (JP) **Report ID:** MRFR/LS/46829-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/india-dry-age-related-macular-degeneration-amd-market-48540 --- ## Market Summary ## **India Dry Age-Related Macular Degeneration (AMD) Market Overview** As per MRFR analysis, the India Dry Age-Related Macular Degeneration (AMD) Market Size was estimated at 220 (USD Million) in 2024.The India Dry Age-Related Macular Degeneration (AMD) Market Industry is expected to grow from 240(USD Million) in 2025 to 600 (USD Million) by 2035. The India Dry Age-Related Macular Degeneration (AMD) Market CAGR (growth rate) is expected to be around 8.687% during the forecast period (2025 - 2035). ## **Key India Dry Age-Related Macular Degeneration (AMD) Market Trends Highlighted** The India Dry Age-Related Macular Degeneration (AMD) Market is witnessing several important market trends influenced by the growing elderly population and increasing awareness of ocular health. As the elderly demographic in India expands, more individuals are affected by vision-related issues, making AMD a significant public health concern. The government's initiatives to promote eye health and regular screenings are helping to raise awareness about AMD, which in turn is driving the demand for diagnostic tools and treatment options.  Furthermore, the rising income levels and changing lifestyles have led to an increase in health spending among the population. Opportunities exist to explore innovative treatment modalities and enhanced diagnostic techniques tailored to the Indian context. The adaptation of advanced technologies for local use, such as telemedicine and mobile health applications, presents a promising avenue for improving access to AMD care. Additionally, there is a significant need for affordable treatment options, including nutritional supplements and minimally invasive procedures, which can cater to the diverse income levels across the population. Recent times have seen an uptick in research and development efforts directed towards AMD, with both public and private sectors investing in studies that aim to better understand the disease and its treatment. Specific approaches towards AMD therapy are being developed in India owing to the expanding pharmaceutical and biotechnology industries in the country. These factors form the basis of the multidisciplinary approach which deals with the problems posed by Dry AMD in India. Collaborations between educational and health institutions are very important for innovation in this area, which certainly demonstrates an attempt to manage AMD issues within the Indian healthcare system. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **India Dry Age-Related Macular Degeneration (AMD) Market Drivers** Increasing Prevalence of Age-Related Macular Degeneration (AMD) in India The rising prevalence of Age-Related Macular Degeneration (AMD) in India is a significant driver for the India Dry Age-Related Macular Degeneration (AMD) Market Industry. According to the National Programme for Control of Blindness and Visual Impairment (NPCBVI), around 7.6 million people in India are affected by AMD, with a projected annual increase due to the aging population. With India's elderly population expected to reach 300 million by 2030, focusing on prevention, awareness, and treatment approaches will be essential. The Indian government has recognized the need for comprehensive eye health care, which emphasizes early detection and management of AMD, thus catalyzing market growth. Furthermore, established organizations such as the All India Ophthalmological Society have been advancing research and awareness initiatives to tackle the rising cases of AMD, underlining the urgency and potential for market expansion. Increasing governmental and non-governmental efforts to manage AMD signify a crucial market growth factor. Technological Advancements in AMD Treatments Technological advancements in treatments for AMD are propelling growth in the India Dry Age-Related Macular Degeneration (AMD) Market Industry. The emergence of innovative therapies such as anti-VEGF injections and gene therapy has shown significant efficacy in combating the effects of AMD. Recent studies indicate that the use of intravitreal injections can reduce the risk of vision loss by up to 50%. Organizations like the Indian Health Ministry are supporting the integration of these advanced treatments into healthcare policies, ensuring broader accessibility for patients.Collaborations between healthcare systems and technology firms are further enhancing treatment options, fostering a conducive environment for the growth of the AMD market in India. Growing Awareness and Screening Initiatives for Eye Health Growing awareness and screening initiatives for eye health in India have significantly contributed to the growth of the India Dry Age-Related Macular Degeneration (AMD) Market Industry. Government campaigns, such as those initiated by NPCBVI, have focused on educating the public about the importance of regular eye check-ups and early detection of AMD. The uptake of eye screening programs has increased, with reports showing nearly 20% of the urban population participating in annual eye examinations, according to the Vision 2020 initiative.NGOs and eye care associations have also been pivotal in conducting awareness programs, leading to a rise in early diagnosis and intervention, which directly increases the demand for AMD-related treatment options. Supportive Government Policies and Funding for Eye Health Supportive government policies and dedicated funding for eye health are critical drivers of the India Dry Age-Related Macular Degeneration (AMD) Market Industry. The Indian government has allocated resources to enhance eye care services under the National Health Mission, focusing on reducing the burden of visual impairment caused by AMD. Increased allocation, estimated to enhance the existing healthcare budget by 15%, aims to improve access to diagnosis and treatment facilities nationwide.Collaborations with organizations like the World Health Organization and local health boards are strengthening policy frameworks and initiatives, indicating strong government backing that favors the AMD sector’s growth. This environment promotes investment in research and treatment infrastructure, further stimulating market expansion. ## **India Dry Age-Related Macular Degeneration (AMD) Market Segment Insights** ### **Dry Age-Related Macular Degeneration (AMD) Market Stage Insights** The India [Dry Age-Related Macular Degeneration (AMD) Market](../../../reports/dry-age-related-macular-degeneration-amd-market-10657) segmentation around the Stage dimension reveals significant insights into the prevalence and impact of this condition on the population. Age-related macular degeneration is primarily classified into three stages: early, intermediate, and late, each reflecting varying levels of severity and visual impairment potential. The early stage is often asymptomatic, yet it serves as a crucial phase where early intervention can help slow down the progression of the disease.  This stage is characterized by the presence of drusen, or yellow deposits, under the retina, which suggest underlying retinal changes. The importance of this phase lies in the opportunity for preventive measures that can significantly influence patient outcomes, as awareness and management at this stage can limit future complications. Moving to the intermediate stage, this phase exhibits noticeable changes in vision, and patients may begin experiencing blurred vision or difficulty in reading. This stage is significant as it represents a critical juncture where medical attention can greatly affect the disease trajectory. Nutritional intervention, alongside advanced treatments available in the market, can help retain vision longer, showcasing the shifting trends towards preventative eye care in India. Moreover, understanding this stage helps healthcare providers to strategize their approach educating patients about regular eye exams and implementing lifestyle changes that may mitigate further risks. In contrast, the late stage of age-related macular degeneration poses the highest threat to vision, often culminating in severe visual impairment. This stage is marked by significant damage to the macula, resulting in the loss of central vision which dramatically impacts daily activities such as reading, driving, and recognizing faces. The late stage tends to demand higher healthcare engagement and forms a crucial focus for healthcare policies given the aging population in India. With increasing life expectancy and a growing elderly demographic, the late stage reflects a pressing public health concern and necessitates robust interventions, including specialized treatment options and home care services. The trends within these stages highlight a broader societal shift towards addressing vision-related health challenges within India. Healthcare providers and policymakers are increasingly recognizing the need for comprehensive care strategies that encompass early detection, community awareness programs, and access to therapeutic modalities. Moreover, emerging technologies in diagnostics and treatment present considerable opportunities in enhancing patient care while also driving market growth in the India Dry Age-Related Macular Degeneration (AMD) Market.  These insights underline not only the importance of understanding each stage of dry AMD but also the interconnectedness of healthcare advancements, community education, and public health initiatives aimed at curtailing the impact of this progressive disease in India. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Dry Age-Related Macular Degeneration (AMD) Market Age Group Insights** The India Dry Age-Related Macular Degeneration (AMD) Market exhibits notable dynamics across various age groups, especially as the population ages and the prevalence of this condition increases. Individuals above 75 years form a significant proportion of those affected by AMD, as age is a primary risk factor. This age category often has limited access to comprehensive eye care, which underscores the importance of expanding health resources and awareness campaigns tailored to their needs. In the group above 60 years, the prevalence remains high, indicating a growing demand for preventive care and treatment options.  This age bracket is also characterized by an increasing interest in innovative healthcare solutions that improve quality of life for individuals facing vision impairments. While the above 40 segment constitutes a smaller part of the patient demographic, early diagnosis and intervention in this category can lead to better management of AMD symptoms, representing a crucial opportunity for healthcare providers to engage with younger patients. Thus, the segmentation by age group within the India Dry Age-Related Macular Degeneration (AMD) Market reveals distinct needs and opportunities for health services, directly influencing market growth and development strategies. ### **Dry Age-Related Macular Degeneration (AMD) Market Diagnosis and Treatment Insights** The Diagnosis and Treatment segment of the India Dry Age-Related Macular Degeneration (AMD) Market plays a crucial role in managing this prevalent eye condition that significantly affects the aging population. As a country with a rapidly growing elderly demographic, the demand for effective diagnostic solutions and treatments in the context of AMD is on the rise. Diagnosis options often include advanced imaging techniques that enable early detection, which is vital in preventing vision loss. The treatment sector encompasses various therapeutic modalities, including anti-VEGF therapies, which have shown promising results in slowing disease progression. A growing awareness among the public and healthcare professionals about the importance of early diagnosis can drive significant advancements in these areas. Government initiatives aimed at improving healthcare access, combined with a significant rise in ophthalmology research and development, bolster the potential for growth in the Diagnosis and Treatment segment. The ongoing evolution of diagnostic devices and treatment options further reinforces the significance of this segment within the broader India Dry Age-Related Macular Degeneration (AMD) Market, presenting promising opportunities for market participants. ### **Dry Age-Related Macular Degeneration (AMD) Market Route of Administration Insights** The India Dry Age-Related Macular Degeneration (AMD) Market, through the Route of Administration segment reflects diverse therapeutic approaches that are pivotal in managing this chronic eye condition. Oral formulations and injectables constitute the primary methods for delivering AMD treatments, each offering distinct benefits and implications for patient adherence and clinical outcomes. Oral medications are often favored for their ease of administration, promoting patient compliance and convenience, while injectables, particularly intravitreal injections, are recognized for their targeted action and effectiveness in delivering therapies directly to the affected area. This phenomenon is increasingly critical in a population where AMD prevalence continues to rise, driven by an aging demographic and lifestyle factors. The rising awareness about vision health in India, supported by government initiatives and healthcare campaigns, furthers the importance of these delivery methods, especially as they align with ongoing Research and Development efforts to enhance treatment efficacy. Overall, as the focus on innovative therapies intensifies, understanding the precise dynamics of the Route of Administration will be essential in shaping the future landscape of the India Dry Age-Related Macular Degeneration (AMD) Market. ### **Dry Age-Related Macular Degeneration (AMD) Market End Users Insights** The India Dry Age-Related Macular Degeneration (AMD) Market is significantly influenced by its End Users, primarily hospitals and clinics, diagnostic centers, and academic and research institutes. Hospitals and clinics form a critical backbone for AMD management, providing essential care and treatment options to patients. Their extensive infrastructure facilitates early diagnosis and ongoing patient management, thus contributing to better health outcomes. Additionally, diagnostic centers play a pivotal role in the precise identification of AMD through advanced imaging techniques, which is vital for the timely initiation of treatment. Academic and research institutes are crucial for the evolution of this field, driving innovation through Research and Development and improving understanding of AMD through studies and clinical trials. The collaboration among these segments fosters a robust ecosystem in the India Dry Age-Related Macular Degeneration (AMD) Market, addressing both patient needs and market growth. With the increasing prevalence of AMD and rising awareness regarding eye health, these End Users are poised to play an ever more significant role in shaping the landscape of AMD treatment and management across India. **India Dry Age-Related Macular Degeneration (AMD) Market Key Players and Competitive Insights:** The India Dry Age-Related Macular Degeneration (AMD) Market is characterized by various competitive dynamics fueled by the rising prevalence of age-related disorders and the growing elderly population. Numerous companies operate within this space, each vying for market share through innovative product offerings, strategic partnerships, and investment in research and development. The competitive landscape is further influenced by technological advancements, customer needs for improved treatment options, and the healthcare ecosystem's overall regulatory environment. Companies are also focusing on enhancing patient outcomes and addressing the challenges posed by this degenerative condition, thereby leading to increased competition. Alcon holds a significant position in the India Dry Age-Related Macular Degeneration (AMD) Market and known for its strong commitment to ophthalmic surgeries and eye care products. The company’s strengths lie in its diversified portfolio of advanced treatment options, including surgical devices and pharmaceuticals specifically designed for retinal diseases. Alcon's extensive experience in the industry enables it to leverage its research capabilities to develop innovative solutions that address the unmet needs of AMD patients.  Furthermore, Alcon has established a robust distribution network across India, which enhances its market presence and allows for effective engagement with healthcare professionals and patients alike. This strong market footprint, combined with a commitment to quality and innovation, ensures that Alcon remains a formidable player in the landscape of AMD treatments in India.Zeiss also plays a crucial role in the India Dry Age-Related Macular Degeneration (AMD) Market, recognized for its expertise in optical and optoelectronic technologies. The company offers a range of key products that cater to AMD, including diagnostic instruments and advanced imaging solutions that aid in the early detection and monitoring of the disease.  Zeiss's strengths include its strong brand recognition and a longstanding reputation for precision and quality, which resonate well with both healthcare providers and patients. The company’s ongoing innovation efforts, coupled with strategic partnerships for research and development, bolster its competitive position in the market. In recent years, Zeiss has engaged in several collaborations aimed at expanding its product offerings and enhancing patient care solutions specific to AMD. These initiatives have not only strengthened its market presence in India but also facilitated its growth trajectory in line with the evolving demands of eye care professionals and their patients. **Key Companies in the India Dry Age-Related Macular Degeneration (AMD) Market Include:** **India Dry Age-Related Macular Degeneration (AMD) Market Industry Developments** The India Dry Age-Related Macular Degeneration (AMD) Market has seen significant developments recently. The demand for innovative treatment options is increasing, driven by the growing aging population, which is a key contributor to AMD prevalence in India. In October 2023, Alcon launched a new diagnostic tool specifically tailored for early detection of AMD, enhancing early intervention capabilities. Moreover, Zeiss introduced advanced imaging technologies aimed at improving the understanding of AMD progression, further impacting diagnostics. In terms of mergers and acquisitions, there have been noteworthy movements; in July 2023, Horizon Therapeutics announced its acquisition of a biotech company specializing in ocular diseases, which could bolster its AMD product pipeline.  Furthermore, Regeneron Pharmaceuticals experienced a growth in its market valuation due to successful trial outcomes for its treatments aimed at retinal diseases, establishing it as a strong competitor in the AMD sector. The Indian government, recognizing the rising burden of eye diseases, is also pushing initiatives to improve healthcare services, which is expected to facilitate growth and accessibility of AMD treatments across the country. ## **India Dry Age-Related Macular Degeneration (AMD) Market Segmentation Insights** ### **Dry Age-Related Macular Degeneration (AMD) Market Stage****Outlook** ### **Dry Age-Related Macular Degeneration (AMD) Market Age Group****Outlook** ### **Dry Age-Related Macular Degeneration (AMD) Market Diagnosis and Treatment****Outlook** ### **Dry Age-Related Macular Degeneration (AMD) Market Route of Administration****Outlook** ### **Dry Age-Related Macular Degeneration (AMD) Market End Users****Outlook** ## Market Drivers ### Aging Population in India The demographic shift towards an older population in India is a crucial driver for the dry age-related-macular-degeneration-amd market. As life expectancy increases, the prevalence of age-related diseases, including AMD, is likely to rise. Reports indicate that by 2030, the population aged 60 and above in India is expected to reach approximately 300 million, which could lead to a significant increase in AMD cases. This growing segment of the population may require enhanced healthcare services and treatment options, thereby driving demand in the dry age-related-macular-degeneration-amd market. Furthermore, the aging population may lead to increased healthcare expenditure, with estimates suggesting that healthcare costs for elderly individuals could rise by 20% annually, further propelling the market's growth. ### Rising Healthcare Expenditure India's increasing healthcare expenditure is another significant driver for the dry age-related-macular-degeneration-amd market. The government and private sectors are investing more in healthcare infrastructure and services, which is likely to improve access to eye care and AMD treatments. In recent years, healthcare spending in India has grown to about 3.5% of GDP, with projections indicating a potential increase to 5% by 2025. This rise in expenditure may facilitate the development of advanced treatment options and technologies for AMD, thereby enhancing patient outcomes. Additionally, as more individuals seek treatment for AMD, the market could experience a surge in demand for innovative therapies and preventive measures, further stimulating growth in the dry age-related-macular-degeneration-amd market. ### Advancements in Diagnostic Technologies Technological innovations in diagnostic tools are transforming the landscape of the dry age-related-macular-degeneration-amd market. Enhanced imaging techniques, such as [optical coherence tomography](https://www.marketresearchfuture.com/reports/optical-coherence-tomography-market-1328) (OCT), are enabling earlier detection and more accurate monitoring of AMD. These advancements are crucial, as early intervention can significantly improve patient outcomes. The adoption of such technologies in India is expected to rise, driven by both public and private healthcare initiatives aimed at improving eye care services. As diagnostic capabilities expand, the market may witness a surge in demand for effective treatment options, as healthcare providers become more equipped to identify and manage AMD cases promptly. ### Increased Incidence of Chronic Diseases The correlation between chronic diseases and the prevalence of AMD is becoming increasingly evident in India. Conditions such as diabetes and hypertension, which are on the rise, have been linked to a higher risk of developing AMD. With diabetes prevalence projected to reach 134 million by 2045 in India, the potential for increased AMD cases is substantial. This trend suggests that as the population grapples with chronic health issues, the demand for AMD-related treatments will likely escalate. Consequently, the dry age-related-macular-degeneration-amd market may see a corresponding increase in the need for specialized care and management strategies tailored to patients with chronic diseases. ### Growing Awareness and Education Initiatives The increasing focus on public health education regarding eye health is a vital driver for the dry age-related-macular-degeneration-amd market. Various organizations and government bodies are launching awareness campaigns to educate the population about AMD and its risk factors. These initiatives aim to inform individuals about the importance of regular eye check-ups and early detection. As awareness grows, more people are likely to seek medical advice and treatment for AMD, potentially leading to a rise in market demand. Furthermore, educational programs targeting healthcare professionals may enhance the quality of care provided to AMD patients, thereby positively impacting the dry age-related-macular-degeneration-amd market. ## Future Outlook The dry age-related macular degeneration market in India is projected to grow at 8.3% CAGR from 2025 to 2035, driven by increasing aging population and advancements in treatment options. **New opportunities:** - Development of [telemedicine](https://www.marketresearchfuture.com/reports/telemedicine-market-2216) platforms for remote consultations and monitoring. - Investment in AI-driven diagnostic tools for early detection and personalized treatment. - Expansion of patient education programs to enhance awareness and treatment adherence. By 2035, the market is expected to achieve substantial growth, driven by innovation and increased healthcare access. ## Segment Insights ### By Stages: Intermediate Age-Related Macular Degeneration (Largest) vs. Late Age-Related Macular Degeneration (Fastest-Growing) In the India dry age-related-macular-degeneration-amd market, the segment for Intermediate Age-Related Macular Degeneration holds the largest market share, reflecting a significant portion of the overall AMD cases. Early Age-Related Macular Degeneration follows, representing a crucial segment that requires early intervention strategies. Late Age-Related Macular Degeneration, while smaller in share, indicates an awareness of the disease progression and the need for advanced treatment options available to patients. Growth trends within this segment highlight the increasing incidence of AMD as the population ages, leading to heightened demand for screening and treatment solutions. Advances in medical technology and a growing understanding of the disease's mechanisms are driving research and product development. Additionally, rising healthcare awareness is propelling patient engagement and access to innovative therapies, stimulating market growth across all stages. Early Age-Related Macular Degeneration (Dominant) vs. Late Age-Related Macular Degeneration (Emerging) Early Age-Related Macular Degeneration serves as the dominant segment due to its pivotal role in initial AMD diagnosis and treatment. This segment emphasizes the importance of early detection, leading to better patient outcomes with timely interventions. The market is characterized by a variety of treatment options that are becoming increasingly innovative, reflecting heightened awareness among both healthcare providers and patients. In contrast, Late Age-Related Macular Degeneration is emerging rapidly as its prevalence increases among the aging population, driven by late-stage treatment needs. This segment is seeing the introduction of advanced therapies, which are pivotal in addressing severe cases and improving quality of life, thus marking substantial growth potential in the long term. ### By Age Group: Above 75 Years (Largest) vs. Above 60 Years (Fastest-Growing) In the India dry age-related-macular-degeneration-amd market, the age group above 75 years holds the largest share, significantly influencing the overall dynamics. This segment indicates a higher prevalence of AMD, making it critical in shaping market trends and strategies for treatment and management efforts. In comparison, the above 60 years category is emerging as the fastest-growing segment, showcasing a noticeable increase in awareness and diagnosis rates, driving market penetration and growth potential. The increasing aging population, along with enhanced healthcare access, is promoting growth within these age demographics. The emergence of novel treatment options specifically tailored for the older population is also propelling market trends. Health initiatives aimed at preventative care are raising awareness, leading to early diagnosis and an uptick in demand for AMD solutions among those aged 60 and above, further solidifying their essential role in the market. Above 75 Years: Dominant vs. Above 60 Years: Emerging The age group above 75 years is dominant in the India dry age-related-macular-degeneration-amd market, as it faces the highest risk of developing this condition. Patients in this category often experience severe vision impairment, leading to significant healthcare needs. This segment's characteristics include a substantial reliance on advanced treatment options and increased healthcare consultations. Meanwhile, the above 60 years group is emerging as an influential player due to a rise in the number of diagnosed cases and increased awareness about AMD. This segment benefits from proactive health measures and educational campaigns, resulting in higher engagement with healthcare services. Together, both age groups shape critical strategic approaches for market stakeholders. ### By Route of Administration: Injectables (Largest) vs. Oral (Fastest-Growing) In the India dry age-related-macular-degeneration-amd market, injectables hold the largest market share, as they are widely preferred for their targeted delivery and rapid action in treating conditions. The preference for injectables is driven by their efficacy in delivering [active ingredients](https://www.marketresearchfuture.com/reports/active-ingredients-market-10702) directly into the bloodstream, leading to immediate therapeutic effects on age-related conditions. In contrast, oral formulations, while growing rapidly, offer convenience and broader accessibility to patients, contributing to their increasing popularity in the market. The growth trends within this segment highlight a significant shift towards injectables due to advancements in formulations and delivery methods that enhance patient outcomes. The oral route, meanwhile, is emerging as a viable alternative for those seeking ease of administration, particularly for long-term treatment regimens. Increasing patient adherence and preference for non-invasive options are fueling the demand for oral formulations, expected to see continued growth in the coming years. Administration Route: Injectables (Dominant) vs. Oral (Emerging) Injectables are currently the dominant administration route in the India dry age-related-macular-degeneration-amd market, noted for their effectiveness and rapid onset of action. They are particularly favored in clinical settings where precise dosage and rapid absorption are critical. The technology used in injectable formulations has improved significantly, ensuring patient comfort and minimizing side effects. On the other hand, oral formulations are emerging as a preferred choice among patients who value convenience and safety in self-administration. As pharmaceutical advancements continue, oral drugs are being developed with enhanced bioavailability and targeted delivery mechanisms, making them increasingly competitive within the market. ### By End Users: Hospitals & Clinics (Largest) vs. Diagnostic Centers (Fastest-Growing) In the India dry age-related-macular-degeneration-amd market, the market share is predominantly held by hospitals and clinics, which are recognized for their comprehensive eye care services and advanced treatment methodologies. This segment's robust infrastructure and established patient base contribute significantly to its leading position in terms of market share. Conversely, diagnostic centers are emerging as a vital segment, capitalizing on their specialized diagnostic capabilities and patient-centric services. Their share, while currently smaller, is rapidly increasing as awareness about early detection grows. Growth trends in this segment are driven by the increasing prevalence of age-related macular degeneration, coupled with a growing aging population seeking specialized care. Hospitals and clinics benefit from established referral networks and trusted patient relationships, while diagnostic centers are expanding their role in early diagnosis and screening services. The demand for advanced diagnostic tools and technologies within these settings further fuels their growth, positioning them as critical players in the overall market. Hospitals & Clinics (Dominant) vs. Diagnostic Centers (Emerging) Hospitals and clinics represent the dominant segment in the India dry age-related-macular-degeneration-amd market, characterized by their comprehensive range of services, skilled ophthalmologists, and access to cutting-edge treatment facilities. Their ability to provide integrated care, from diagnosis to surgical interventions, positions them favorably within the healthcare landscape. On the other hand, diagnostic centers are emerging as key contributors, focusing primarily on advanced screening and diagnostic procedures. Their growth is spurred by technological innovation and a rising demand for efficient, patient-friendly services. As awareness of the condition increases, these centers are enhancing their offerings, thus playing a pivotal role in early diagnosis and management, fostering collaboration with hospitals to create a continuum of care for affected patients. ## Competitive Benchmarking The dry age-related macular degeneration (AMD) market in India is characterized by a competitive landscape that is increasingly shaped by innovation and strategic partnerships. Key growth drivers include an aging population, rising awareness of eye health, and advancements in treatment options. Major players such as Regeneron Pharmaceuticals (US), Novartis (CH), and Roche (CH) are actively positioning themselves through a combination of research and development, regional expansion, and collaborations with local healthcare providers. Their collective strategies not only enhance their market presence but also foster a more competitive environment that encourages continuous improvement in treatment efficacy and accessibility.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and improve supply chain efficiency. The market structure appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for a diverse range of treatment options, yet it also necessitates that companies differentiate themselves through unique value propositions and operational excellence. In October Regeneron Pharmaceuticals (US) announced a partnership with a leading Indian healthcare provider to enhance the distribution of its innovative AMD therapies. This strategic move is likely to improve patient access to cutting-edge treatments, thereby solidifying Regeneron’s position in the market. The collaboration underscores the importance of local partnerships in navigating the complexities of the Indian healthcare landscape.Similarly, in September 2025, Novartis (CH) launched a new digital platform aimed at educating patients and healthcare professionals about AMD. This initiative not only reflects Novartis's commitment to patient engagement but also positions the company as a thought leader in the field. By leveraging digital tools, Novartis may enhance its brand loyalty and drive demand for its AMD therapies.Moreover, in August 2025, Roche (CH) expanded its clinical trial program in India, focusing on a novel treatment for dry AMD. This expansion is indicative of Roche's long-term commitment to the Indian market and its strategy to invest in local research capabilities. By doing so, Roche could potentially accelerate the development of new therapies tailored to the specific needs of Indian patients. As of November current competitive trends in the dry AMD market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in treatment development. Strategic alliances are becoming more prevalent, allowing companies to pool resources and expertise to tackle complex challenges. Looking ahead, it appears that competitive differentiation will increasingly hinge on innovation and technology rather than price. Companies that prioritize supply chain reliability and invest in cutting-edge research are likely to emerge as leaders in this evolving landscape. ## Recent News & Developments The India Dry Age-Related Macular Degeneration (AMD) Market has seen significant developments recently. The demand for innovative treatment options is increasing, driven by the growing aging population, which is a key contributor to AMD prevalence in India. In October 2023, Alcon launched a new diagnostic tool specifically tailored for early detection of AMD, enhancing early intervention capabilities. Moreover, Zeiss introduced advanced imaging technologies aimed at improving the understanding of AMD progression, further impacting diagnostics. In terms of mergers and acquisitions, there have been noteworthy movements; in July 2023, Horizon Therapeutics announced its acquisition of a biotech company specializing in ocular diseases, which could bolster its AMD product pipeline.  Furthermore, Regeneron Pharmaceuticals experienced a growth in its market valuation due to successful trial outcomes for its treatments aimed at retinal diseases, establishing it as a strong competitor in the AMD sector. The Indian government, recognizing the rising burden of eye diseases, is also pushing initiatives to improve healthcare services, which is expected to facilitate growth and accessibility of AMD treatments across the country. ## Report Scope | MARKET SIZE 2024 | 238.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 257.75(USD Million) | | MARKET SIZE 2035 | 572.12(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.3% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Regeneron Pharmaceuticals (US), Novartis (CH), Roche (CH), Bayer (DE), Pfizer (US), Alcon (CH), Horizon Therapeutics (IE), Apellis Pharmaceuticals (US), Santen Pharmaceutical (JP) | | Segments Covered | Stages, Age Group, Route of Administration, End Users | | Key Market Opportunities | Emerging therapies and digital health solutions enhance patient management in the dry age-related-macular-degeneration-amd market. | | Key Market Dynamics | Rising prevalence of dry age-related macular degeneration drives demand for innovative treatment options and enhanced patient care. | | Countries Covered | India | ## Frequently Asked Questions **Q: What is the current market valuation of the India dry age-related macular degeneration market?** A: The market valuation was $238.0 Million in 2024. **Q: What is the projected market size for the India dry age-related macular degeneration market by 2035?** A: The projected market size is $572.12 Million by 2035. **Q: What is the expected CAGR for the India dry age-related macular degeneration market during the forecast period 2025 - 2035?** A: The expected CAGR is 8.3% during the forecast period 2025 - 2035. **Q: Which age group shows the highest market valuation in the India dry age-related macular degeneration market?** A: The age group above 40 years had a market valuation of $118.0 Million in 2024. **Q: What are the key segments in the India dry age-related macular degeneration market?** A: Key segments include stages, age group, route of administration, and end users. **Q: Which route of administration had the highest market valuation in 2024?** A: Injectables had the highest market valuation of $143.0 Million in 2024. **Q: What is the market valuation for late age-related macular degeneration in 2024?** A: The market valuation for late age-related macular degeneration was $88.0 Million in 2024. **Q: Who are the leading players in the India dry age-related macular degeneration market?** A: Key players include Regeneron Pharmaceuticals, Novartis, Roche, Bayer, and Pfizer. **Q: What is the market valuation for hospitals and clinics as end users in 2024?** A: The market valuation for hospitals and clinics was $100.0 Million in 2024. **Q: What is the projected growth trend for the India dry age-related macular degeneration market?** A: The market is expected to grow significantly, reaching $572.12 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-dry-age-related-macular-degeneration-amd-market-48540*